Nuijens A, Oei A, Franken N, Rasch C, Stalpers L
Curr Oncol. 2025; 32(1).
PMID: 39851963
PMC: 11763857.
DOI: 10.3390/curroncol32010047.
Ng V, Sinha S, Novaj A, Ma J, McDermott N, Pei X
Clin Cancer Res. 2024; 30(24):5643-5656.
PMID: 39109923
PMC: 11702853.
DOI: 10.1158/1078-0432.CCR-24-0154.
Tan J, Sun X, Zhao H, Guan H, Gao S, Zhou P
MedComm (2020). 2023; 4(5):e388.
PMID: 37808268
PMC: 10556206.
DOI: 10.1002/mco2.388.
Vokes N, Cobo A, Fernandez-Chas M, Molkentine D, Trevino 3rd S, Druker V
Clin Cancer Res. 2023; 29(23):4958-4972.
PMID: 37733794
PMC: 10690143.
DOI: 10.1158/1078-0432.CCR-23-1122.
Zuhair Kassem T, Wunderle M, Kuhlmann L, Ruebner M, Huebner H, Hoyer J
Curr Issues Mol Biol. 2023; 45(8):6618-6633.
PMID: 37623237
PMC: 10453196.
DOI: 10.3390/cimb45080418.
Radiology's Ionising Radiation Paradox: Weighing the Indispensable Against the Detrimental in Medical Imaging.
Najjar R
Cureus. 2023; 15(7):e41623.
PMID: 37435015
PMC: 10331516.
DOI: 10.7759/cureus.41623.
Prospective Newborn Screening for SCID in Germany: A First Analysis by the Pediatric Immunology Working Group (API).
Speckmann C, Nennstiel U, Honig M, Albert M, Ghosh S, Schuetz C
J Clin Immunol. 2023; 43(5):965-978.
PMID: 36843153
PMC: 9968632.
DOI: 10.1007/s10875-023-01450-6.
Pancreatic cancer derived 3D organoids as a clinical tool to evaluate the treatment response.
Shukla H, Dukic T, Roy S, Bhandary B, Gerry A, Poirier Y
Front Oncol. 2023; 12:1072774.
PMID: 36713532
PMC: 9879007.
DOI: 10.3389/fonc.2022.1072774.
The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review.
Pereira S, Orlandi E, Deneuve S, Barcellini A, Chalaszczyk A, Behm-Ansmant I
Cancers (Basel). 2022; 14(24).
PMID: 36551737
PMC: 9776433.
DOI: 10.3390/cancers14246252.
Cancer and Radiosensitivity Syndromes: Is Impaired Nuclear ATM Kinase Activity the Primum Movens?.
El Nachef L, Berthel E, Ferlazzo M, Le Reun E, Al-Choboq J, Restier-Verlet J
Cancers (Basel). 2022; 14(24).
PMID: 36551628
PMC: 9776478.
DOI: 10.3390/cancers14246141.
Quantitative Correlations between Radiosensitivity Biomarkers Show That the ATM Protein Kinase Is Strongly Involved in the Radiotoxicities Observed after Radiotherapy.
Le Reun E, Bodgi L, Granzotto A, Sonzogni L, Ferlazzo M, Al-Choboq J
Int J Mol Sci. 2022; 23(18).
PMID: 36142346
PMC: 9498991.
DOI: 10.3390/ijms231810434.
Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy.
Chan Wah Hak C, Rullan A, Patin E, Pedersen M, Melcher A, Harrington K
Front Oncol. 2022; 12:971959.
PMID: 36106115
PMC: 9465159.
DOI: 10.3389/fonc.2022.971959.
Nervous system (NS) Tumors in Cancer Predisposition Syndromes.
Patil P, Pencheva B, Patil V, Fangusaro J
Neurotherapeutics. 2022; 19(6):1752-1771.
PMID: 36056180
PMC: 9723057.
DOI: 10.1007/s13311-022-01277-w.
PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors.
Thomas A, Fontaine S, Diolaiti M, Desai P, Kumar R, Takahashi N
Mol Cancer Ther. 2022; 21(11):1722-1728.
PMID: 35999657
PMC: 10673686.
DOI: 10.1158/1535-7163.MCT-22-0217.
Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung Cancer.
He K, Zhang S, Pang J, Yin J, Mu D, Wang J
Front Oncol. 2022; 12:928605.
PMID: 35912186
PMC: 9329611.
DOI: 10.3389/fonc.2022.928605.
Exploring the genetic space of the DNA damage response for cancer therapy through CRISPR-based screens.
Wilson J, Loizou J
Mol Oncol. 2022; 16(21):3778-3791.
PMID: 35708734
PMC: 9627789.
DOI: 10.1002/1878-0261.13272.
Improving Patients' Life Quality after Radiotherapy Treatment by Predicting Late Toxicities.
Lapierre A, Bourillon L, Larroque M, Gouveia T, Bourgier C, Ozsahin M
Cancers (Basel). 2022; 14(9).
PMID: 35565227
PMC: 9099838.
DOI: 10.3390/cancers14092097.
Metabolic Stress and Mitochondrial Dysfunction in Ataxia-Telangiectasia.
Subramanian G, Yeo A, Gatei M, Coman D, Lavin M
Antioxidants (Basel). 2022; 11(4).
PMID: 35453338
PMC: 9032508.
DOI: 10.3390/antiox11040653.
Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma.
Everix L, Nair S, Driver C, Goethals I, Sathekge M, Ebenhan T
Cancers (Basel). 2022; 14(7).
PMID: 35406593
PMC: 8997380.
DOI: 10.3390/cancers14071821.
Function and Molecular Mechanism of the DNA Damage Response in Immunity and Cancer Immunotherapy.
Ye Z, Shi Y, Lees-Miller S, Tainer J
Front Immunol. 2021; 12:797880.
PMID: 34970273
PMC: 8712645.
DOI: 10.3389/fimmu.2021.797880.
